Ongoing research projects
Investigator clinical trials initiated from our study group (with ongoing clinical/translational analyses)
The DART trial (EudraCT number: 2019-002537-11 ): Biomarker study for adjuvant durvalumab after chemoradiation for patients with stage III non-small cell lung cancer. Recruitment completed.
The NIPU-trial (EudraCT number: 2019-002721-30): Ipilimumab and nivolumab with or without UV1-vaccine for patients with pleural mesothelioma progressing after first-line platinum doublet. Recruitment completed.
The COM-IT-2 trial (EudraCT Number: 2021-003266): Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer. Recruitment ongoing.
The PILoT trial (): Periadjuvant dostarlimab, telomerase vaccine (UV1) with neoadjuvant chemotherapy for patients with stage III non-small cell lung cancer. Recruitment planned Q2 2024.
IMPRESS-Norway (EudraCT number: 2020-004414-35): Pan-cancer investigator-initiated study including many lung cancer patients. Recruitment ongoing.
Other clinical trials with ongoing clinical/translational analyses
ImPRESS-losartan (2018-003229-27): MRI of brain metastases treated with immunotherapy and/or radiotherapy. (Sponsor OUH)
TRIPLEX (EudraCT: 2021-001648-91): Patients with SCLC, extensive disease treated with carboplatin, etoposide and durvalumab and randomized to systemic treatment alone or combined with thoracic radiation. (Sponsor St. Olavs Hospital)
LungVac (EudraCT number: 2021-005729-25): Pembrolizumab/cemiplimab and UV1-vaccine for patients with stage IV NSLC and PD-L1>50% (Sponsor: Vestre Viken)
Solucom (EudraCT: 2021-001696-16): Sotorasib for patients with stage IV NSCLC harboring mutations in KRAS G12C. (Sponsor: Vestre Viken)
LIBRETTO (EudraCT: 2020-005191-35): Patients with local/regional NSCLC harboring RET-fusion after curatively intended treatment with surgery or radiotherapy. Randomisation to selpercatinib or placebo adjuvant. (Sponsor: Eli Lilly and Company)
PACIFIC-8 (2021-004327-32): Patients with stage III NSCLC PD-L1 ≥ 1% after chemoradiation. Randomisation to durvalumab plus placebo or domvanalimab adjuvant. (Sponsor: Astra Zeneca AB)
HORIZON 01: (2023-503920-14-00) Patients with stage III NSCLC with ALK-translocation after chemoradiation. Randomisation to adjuvant treatment with durvalumab 1 year or alectinib 3 years (Sponsor: F. Hoffmann-La Roche Ltd)
Sunray-01/JZQB: (EudraCT: 2023-503412-33-00) First-line treatment for patients with stage IV NSCLC harboring mutation in KRAS G12C randomized to platinum, pembrolizumab and placebo vs pembrolizumab and LY3537982 (chemotherapy is facultative if PD-L1>50%)(Sponsor: Eli Lilly and Company)
Translational research projects
Visit Therapy prediction in lung cancer project group, headed by Vilde Drageset Haakensen